The aim of the present work was to perform a meta-analysis to evaluate the association between the interleukin 10 (IL-10) −819C/T (rs1800871) polymorphism and cancer risk. A total of 73 studies, including 15,942 cancer cases and 22,336 controls, were identified in this meta-analysis. The odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using the random-effects model. Overall, no significant association was identified between the IL-10 −819C/T polymorphism and cancer risk. In the subgroup analyses, the T allele and TT genotype were associated with a moderately reduced cancer risk in the Asian population (T allele vs. C allele: OR=0.93, 95%CI: 0.87, 0.99; TT vs. CC: OR=0.86, 95%CI: 0.76, 0.98; TT vs. CT/CC: OR=0.90, 95%CI: 0.82, 0.98). Individuals who were homozygous for the T allele (TT) were found to be associated with significantly reduced gastric cancer risk in the Asian population. The heterozygous variant (CT) and the dominant model (TT/CT vs. CC) were associated with an increased risk for cervical and ovarian cancer. However, the IL-10 −819C/T polymorphism was not significantly associated with breast cancer, colorectal cancer, lung cancer, hepatocellular carcinoma, prostate cancer, lymphoma, or melanoma. The depressed cancer risk of the TT genotype occurred in the studies of hospital-based case-control studies and the studies recruited less than 500 subjects, but no statistically significant results were found in the stratified analyses using genotyping method. The results suggest that the IL-10 −819TT genotype may be a protective factor for cancer in Asians, especially gastric cancer. In contrast, the CT genotype and the dominant model could be risk factors for cervical and ovarian cancer. The importance of stratifying by ethnicity, cancer type, study design, and sample size needs to be standardized in future studies, together with considering the association between the IL-10 −819C/T polymorphism and cancer risk. Furthermore, the linkage of −819C/T with other polymorphisms of the IL-10 gene may help explain the variability in findings.
Get full access to this article
View all access options for this article.
References
1.
AhirwarD, MandhaniA, MittalRD. 2009. Interleukin-10 G-1082A and C-819T polymorphisms as possible molecular markers of urothelial bladder cancer. Arch Med Res, 40:97–102.
2.
AlonsoR, SuarezA, CastroP, LacaveAJ, GutierrezC. 2005. Influence of interleukin-10 genetic polymorphism on survival rates in melanoma patients with advanced disease. Melanoma Res, 15:53–60.
3.
Alpizar-AlpizarW, Perez-PerezGI, UneC, CuencaP, SierraR. 2005. Association of interleukin-1B and interleukin-1RN polymorphisms with gastric cancer in a high-risk population of Costa Rica. Clin Exp Med, 5:169–176.
4.
AmirzargarAA, BagheriM, GhavamzadehAet al.2005. Cytokine gene polymorphism in Iranian patients with chronic myelogenous leukaemia. Int J Immunogenet, 32:167–171.
5.
AndoT, IshikawaT, KatoHet al.2009. Synergistic effect of HLA class II loci and cytokine gene polymorphisms on the risk of gastric cancer in Japanese patients with Helicobacter pylori infection. Int J Cancer, 125:2595–2602.
6.
BasturkB, YavascaogluI, VuruskanH, GoralG, OktayB, OralHB. 2005. Cytokine gene polymorphisms as potential risk and protective factors in renal cell carcinoma. Cytokine, 30:41–45.
7.
BeiCH, ChouXQ, CengXY, YangY, HuangJM, FanXJ. 2011. [Association of interleukin-10 gene polymorphism with hepatocellular carcinoma]Zhong Guo Gong Gong Wei Sheng, 27:309–311.
8.
BushleyAW, FerrellR, McduffieK, TeradaKY, CarneyME, ThompsonPJet al.2004. Polymorphisms of interleukin (IL)-1alpha, IL-1beta, IL-6, IL-10, and IL-18 and the risk of ovarian cancer. Gynecol Oncol, 95:672–679.
9.
CacevT, RadosevicS, KrizanacS, KapitanovicS. 2008. Influence of interleukin-8 and interleukin-10 on sporadic colon cancer development and progression. Carcinogenesis, 29:1572–1580.
10.
CastroFa, HaimilaK, SarenevaIet al.2009. Association of HLA-DRB1, interleukin-6 and cyclin D1 polymorphisms with cervical cancer in the Swedish population—A candidate gene approach. Int J Cancer, 125:1851–1858.
11.
ChenKF, LiB, WeiYG, PengCJ. 2010. Interleukin-10 −819 promoter polymorphism associated with gastric cancer among Asians. J Int Med Res, 38:1–8.
12.
ChowMT, MollerA, SmythMJ. 2012. Inflammation and immune surveillance in cancer. Semin Cancer Biol, 22:23–32.
13.
ColakogullariM, UlukayaE, Yilmaztepe OralAet al.2008. The involvement of IL-10, IL-6, IFN-gamma, TNF-alpha and TGF-beta gene polymorphisms among Turkish lung cancer patients. Cell Biochem Funct, 26:283–290.
14.
CoussensLM, WerbZ. 2002. Inflammation and cancer. Nature, 420:860–867.
15.
CozarJM, RomeroJM, AptsiauriNet al.2007. High incidence of CTLA-4 AA (CT60) polymorphism in renal cell cancer. Hum Immunol, 68:698–704.
16.
CrivelloA, GiacaloneA, VaglicaMet al.2006. Regulatory cytokine gene polymorphisms and risk of colorectal carcinoma. Ann NY Acad Sci, 1089:98–103.
17.
CrusiusJB, CanzianF, CapellaGet al.2008. Cytokine gene polymorphisms and the risk of adenocarcinoma of the stomach in the European prospective investigation into cancer and nutrition (EPIC-EURGAST)Ann Oncol, 19:1894–1902.
18.
Da SilvaGN, BacchiMM, RainhoCA, De OliveiraDE. 2007. Epstein-Barr virus infection and single nucleotide polymorphisms in the promoter region of interleukin 10 gene in patients with Hodgkin lymphoma. Arch Pathol Lab Med, 131:1691–1696.
19.
De OliveiraWR, RadyPL, GradyJet al.2003. Polymorphisms of the interleukin 10 gene promoter in patients from Brazil with epidermodysplasia verruciformis. J Am Acad Dermatol, 49:639–643.
20.
De VisserKE, EichtenA, CoussensLM. 2006. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer, 6:24–37.
21.
DersimonianR, LairdN. 1986. Meta-analysis in clinical trials. Control Clin Trials, 7:177–188.
22.
EderT, MayerR, LangsenlehnerUet al.2007. Interleukin-10 [ATA] promoter haplotype and prostate cancer risk: A population-based study. Eur J Cancer, 43:472–475.
23.
El-OmarEM, RabkinCS, GammonMDet al.2003. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology, 124:1193–1201.
24.
EskdaleJ, GallagherG, VerweijCL, KeijsersV, WestendorpRG, HuizingaTW. 1998. Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci USA, 95:9465–9470.
25.
Faupel-BadgerJM, KiddLC, AlbanesD, VirtamoJ, WoodsonK, TangreaJA. 2008. Association of IL-10 polymorphisms with prostate cancer risk and grade of disease. Cancer Causes Control, 19:119–124.
26.
FestaF, KumarR, SanyalSet al.2005. Basal cell carcinoma and variants in genes coding for immune response, DNA repair, folate and iron metabolism. Mutat Res, 574:105–111.
27.
FillatreauS, GrayD, AndertonSM. 2008. Not always the bad guys: B cells as regulators of autoimmune pathology. Nat Rev Immunol, 8:391–397.
28.
GonulluG, BasturkB, EvrenselT, OralB, GozkamanA, ManavogluO. 2007. Association of breast cancer and cytokine gene polymorphism in Turkish women. Saudi Med J, 28:1728–1733.
29.
GrivennikovSI, GretenFR, KarinM. 2010. Immunity, inflammation, and cancer. Cell, 140:883–899.
30.
GunterMJ, CanzianF, LandiS, ChanockSJ, SinhaR, RothmanN. 2006. Inflammation-related gene polymorphisms and colorectal adenoma. Cancer Epidemiol Biomarkers Prev, 15:1126–1131.
31.
GuzowskiD, ChandrasekaranA, GawelCet al.2005. Analysis of single nucleotide polymorphisms in the promoter region of interleukin-10 by denaturing high-performance liquid chromatography. J Biomol Tech, 16:154–166.
32.
HeXP, WangLL, ZhaoH, WuD, TangHD, CaoFL. 2008. [Association of interleukin-10 polymorphisms with susceptibility to ovarian cancer in Chinese Han population.]Zhong Guo You Sheng Yu Yi Chuan Za Zhi, 16:37–38.
33.
HellmigS, BartschtT, FischbachW, FolschUR, SchreiberS. 2008. Interleukin-10 (-819 C/T) and TNF-A (-308 G/A) as risk factors for H. pylori-associated gastric MALT-lymphoma. Dig Dis Sci, 53:2007–2008.
HowellWM, TurnerSJ, BatemanAA, TheakerJM. 2001. IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanoma. Genes Immun, 2:25–31.
36.
HubnerRA, MuirKR, LiuJF, LoganRF, GraingeMJ, HoulstonRS. 2007. Polymorphisms in PTGS1, PTGS2 and IL-10 do not influence colorectal adenoma recurrence in the context of a randomized aspirin intervention trial. Int J Cancer, 121:2001–2004.
37.
Ioana BraicuE, MusteaA, ToliatMRet al.2007. Polymorphism of IL-1alpha, IL-1beta and IL-10 in patients with advanced ovarian cancer: Results of a prospective study with 147 patients. Gynecol Oncol, 104:680–685.
38.
IoannidisJP, BoffettaP, LittleJet al.2008. Assessment of cumulative evidence on genetic associations: Interim guidelines. Int J Epidemiol, 37:120–132.
39.
IoannidisJP, PatsopoulosNA, EvangelouE. 2007. Uncertainty in heterogeneity estimates in meta-analyses. BMJ, 335:914–916.
40.
KamangarF, AbnetCC, HutchinsonAAet al.2006. Polymorphisms in inflammation-related genes and risk of gastric cancer (Finland)Cancer Causes Control, 17:117–125.
41.
KangJM, KimN, LeeDHet al.2009. The effects of genetic polymorphisms of IL-6, IL-8, and IL-10 on Helicobacter pylori-induced gastroduodenal diseases in Korea. J Clin Gastroenterol, 43:420–428.
42.
KesarwaniP, AhirwarDK, MandhaniAet al.2009. IL-10 −1082 G>A: A risk for prostate cancer but may be protective against progression of prostate cancer in North Indian cohort. World J Urol, 27:389–396.
43.
KimJ, ChoYA, ChoiIJet al.2012. Effects of interleukin-10 polymorphisms, Helicobacter pylori infection, and smoking on the risk of noncardia gastric cancer. PLoS One, 7.
44.
KongF, LiuJ, LiuY, SongB, WangH, LiuW. 2010. Association of interleukin-10 gene polymorphisms with breast cancer in a Chinese population. J Exp Clin Cancer Res, 29:72.
45.
LanQ, ZhengT, RothmanNet al.2006. Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood, 107:4101–4108.
46.
LangsenlehnerU, KripplP, RennerWet al.2005. Interleukin-10 promoter polymorphism is associated with decreased breast cancer risk. Breast Cancer Res Treat, 90:113–115.
47.
Lech-MarandaE, BaseggioL, CharlotCet al.2007. Genetic polymorphisms in the proximal IL-10 promoter and susceptibility to non-Hodgkin lymphoma. Leuk Lymphoma, 48:2235–2238.
48.
LeeJY, KimHY, KimKHet al.2005. Association of polymorphism of IL-10 and TNF-A genes with gastric cancer in Korea. Cancer Lett, 225:207–214.
49.
LeonA, LeonV, GarciaJ, UrrutiaM. 2010. Interleukin gene polymorphism in patients with prostate cancer. Tissue Antigens, 75:637.
50.
LiangL, ZhaoYL, YueJet al.2011. Interleukin-10 gene promoter polymorphisms and their protein production in pleural fluid in patients with tuberculosis. FEMS Immunol Med Microbiol, 62:84–90.
51.
LiuJ, SongB, BaiXet al.2010a. Association of genetic polymorphisms in the interleukin-10 promoter with risk of prostate cancer in Chinese. BMC Cancer, 10:456.
52.
LiuJ, SongB, WangJL, LiZJ, LiWH, WangZH. 2011. Polymorphisms of interleukin-10 promoter are not associated with prognosis of advanced gastric cancer. World J Gastroenterol, 17:1362–1367.
53.
LiuJJ, GaoYT, DuZet al.2010b. Relationship between IL-10 gene promoter polymorphisms and outcome of hepatitis B virus infection. World Chin J Digestol, 18:1656–1663.
54.
MacarthurM, SharpL, HoldGL, LittleJ, El-OmarEM. 2005. The role of cytokine gene polymorphisms in colorectal cancer and their interaction with aspirin use in the northeast of Scotland. Cancer Epidemiol Biomarkers Prev, 14:1613–1618.
55.
Martinez-EscribanoJA, Moya-QuilesMR, MuroMet al.2002. Interleukin-10, interleukin-6 and interferon-gamma gene polymorphisms in melanoma patients. Melanoma Res, 12:465–469.
56.
MazurG, Bogunia-KubikK, WrobelTet al.2005. IL-6 and IL-10 promoter gene polymorphisms do not associate with the susceptibility for multiple myeloma. Immunol Lett, 96:241–246.
57.
MichaudDS, DaughertySE, BerndtSIet al.2006. Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer. Cancer Res, 66:4525–4530.
58.
MigitaK, MiyazoeS, MaedaYet al.2005. Cytokine gene polymorphisms in Japanese patients with hepatitis B virus infection—Association between TGF-beta1 polymorphisms and hepatocellular carcinoma. J Hepatol, 42:505–510.
59.
MooreKW, De Waal MalefytR, CoffmanRL, O'garraA. 2001. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol, 19:683–765.
60.
MunroLR, JohnstonPW, MarshallNAet al.2003. Polymorphisms in the interleukin-10 and interferon gamma genes in Hodgkin lymphoma. Leuk Lymphoma, 44:2083–2088.
61.
NietersA, YuanJM, SunCLet al.2005. Effect of cytokine genotypes on the hepatitis B virus-hepatocellular carcinoma association. Cancer, 103:740–748.
62.
O'garraA, VieiraP. 2007. T(H)1 cells control themselves by producing interleukin-10. Nat Rev Immunol, 7:425–428.
63.
PerssonC, CanedoP, MachadoJC, El-OmarEM, FormanD. 2011. Polymorphisms in inflammatory response genes and their association with gastric cancer: A HuGE systematic review and meta-analyses. Am J Epidemiol, 173:259–270.
64.
PharoahPD, DunningAM, PonderBA, EastonDF. 2004. Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer, 4:850–860.
65.
PharoahPD, TyrerJ, DunningAM, EastonDF, PonderBA. 2007. Association between common variation in 120 candidate genes and breast cancer risk. PLoS Genet, 3:e42.
66.
PogodaTV, MarshevaOV, KostinPAet al.2007. Association of haplotypes of interleukin-10 gene with the risk of cancer. Bull Exp Biol Med, 144:385–389.
67.
PratesiC, BortolinMT, BidoliEet al.2006. Interleukin-10 and interleukin-18 promoter polymorphisms in an Italian cohort of patients with undifferentiated carcinoma of nasopharyngeal type. Cancer Immunol Immunother, 55:23–30.
68.
PurdueMP, LanQ, KrickerA, GrulichAE, VajdicCm, TurnerJet al.2007. Polymorphisms in immune function genes and risk of non-Hodgkin lymphoma: Findings from the New South Wales non-Hodgkin Lymphoma Study. Carcinogenesis, 28:704–712.
69.
RohJW, KimMH, SeoSSet al.2002. Interleukin-10 promoter polymorphisms and cervical cancer risk in Korean women. Cancer Lett, 184:57–63.
70.
RyanJJ, KashyapM, BaileyDet al.2007. Mast cell homeostasis: A fundamental aspect of allergic disease. Crit Rev Immunol, 27:15–32.
71.
SavageSA, AbnetCC, HaqueKet al.2004. Polymorphisms in interleukin −2, −6, and −10 are not associated with gastric cardia or esophageal cancer in a high-risk Chinese population. Cancer Epidemiol Biomarkers Prev, 13:1547–1549.
72.
SeifartC, PlagensA, DempfleAet al.2005. TNF-alpha, TNF-beta, IL-6, and IL-10 polymorphisms in patients with lung cancer. Dis Markers, 21:157–165.
73.
ShaoN, XuB, MiYY, HuaLX. 2011. IL-10 polymorphisms and prostate cancer risk: A meta-analysis. Prostate Cancer Prostatic Dis, 14:129–135.
74.
ShihCM, LeeYL, ChiouHLet al.2005. The involvement of genetic polymorphism of IL-10 promoter in non-small cell lung cancer. Lung Cancer, 50:291–297.
75.
ShinHD, ParkBL, KimLHet al.2003. Interleukin 10 haplotype associated with increased risk of hepatocellular carcinoma. Hum Mol Genet, 12:901–906.
76.
SicinschiLA, Lopez-CarrilloL, CamargoMCet al.2006. Gastric cancer risk in a Mexican population: Role of Helicobacter pylori CagA positive infection and polymorphisms in interleukin-1 and −10 genes. Int J Cancer, 118:649–657.
77.
SinghH, JainM, SachanR, MittalB. 2009. Association of TNFA (-308G>A) and IL-10 (-819C>T) promoter polymorphisms with risk of cervical cancer. Int J Gynecol Cancer, 19:1190–1194.
78.
SpitsH, De Waal MalefytR. 1992. Functional characterization of human IL-10. Int Arch Allergy Immunol, 99:8–15.
79.
SterneJA, GavaghanD, EggerM. 2000. Publication and related bias in meta-analysis: Power of statistical tests and prevalence in the literature. J Clin Epidemiol, 53:1119–1129.
80.
SuSP, YangZB, TianYL. 2010. Relationship between polymorphisms of IL-1(beta)-31, IL-10-819 and TNF-(alpha)-1031 genes and susceptibilities to H. pylori infection-associated gastric ulcer and cancer. Chin J Biol, 23:517–520.
81.
SugimotoM, FurutaT, ShiraiNet al.2007. Effects of interleukin-10 gene polymorphism on the development of gastric cancer and peptic ulcer in Japanese subjects. J Gastroenterol Hepatol, 22:1443–1449.
82.
TsengLH, LinMT, ShauWYet al.2006. Correlation of interleukin-10 gene haplotype with hepatocellular carcinoma in Taiwan. Tissue Antigens, 67:127–133.
83.
TurnerDMm, WilliamsDM, SankaranD, LazarusM, SinnottPJ, HutchinsonIV. 1997. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet, 24:1–8.
84.
VancleaveTT, MooreJH, BenfordMLet al.2010. Interaction among variant vascular endothelial growth factor (VEGF) and its receptor in relation to prostate cancer risk. Prostate, 70:341–352.
85.
VishnoiM, ChoudhuriG, MittalB. 2007. Is IL-10 −819C/T gene polymorphism modulating the risk of gallbladder disease in North Indian population?J Gastrointest Cancer, 38:46–51.
86.
VogelU, ChristensenJ, DybdahlMet al.2007. Prospective study of interaction between alcohol, NSAID use and polymorphisms in genes involved in the inflammatory response in relation to risk of colorectal cancer. Mutat Res, 624:88–100.
87.
VogelU, ChristensenJ, WallinHet al.2008. Polymorphisms in genes involved in the inflammatory response and interaction with NSAID use or smoking in relation to lung cancer risk in a prospective study. Mutat Res, 639:89–100.
88.
WangMH, HelzlsouerKJ, SmithMWet al.2009. Association of IL10 and other immune response- and obesity-related genes with prostate cancer in CLUE II. Prostate, 69:874–885.
89.
WeiYG, LiuF, LiBet al.2011. Interleukin-10 gene polymorphisms and hepatocellular carcinoma susceptibility: A meta-analysis. World J Gastroenterol, 17:3941–3947.
90.
WeiYS, KuangXH, ZhuYHet al.2007. Interleukin-10 gene promoter polymorphisms and the risk of nasopharyngeal carcinoma. Tissue Antigens, 70:12–17.
WuMS, WuCY, ChenCJ, LinMT, ShunCT, LinJT. 2003. Interleukin-10 genotypes associate with the risk of gastric carcinoma in Taiwanese Chinese. Int J Cancer, 104:617–623.
93.
XiaoH, LiC, JiangY, LiR, XiaB. 2009. [The relationship among IL-10, TNF gene polymorphisms, Helicobacter pylori infection and gastroduodenal diseases in Hubei Han ethnic]Zhonghua Nei Ke Za Zhi, 48:552–556.
94.
XueH, LinB, AnJ, ZhuY, HuangG. 2012. Interleukin-10-819 promoter polymorphism in association with gastric cancer risk. BMC Cancer, 12:102.
95.
YaoJG, GaoLB, LiuYG, LiJ, PangGF. 2008. Genetic variation in interleukin-10 gene and risk of oral cancer. Clin Chim Acta, 388:84–88.
96.
ZabaletaJ, LinHY, SierraRAet al.2008. Interactions of cytokine gene polymorphisms in prostate cancer risk. Carcinogenesis, 29:573–578.
97.
ZambonCF, BassoD, NavagliaFet al.2005. Pro- and anti-inflammatory cytokines gene polymorphisms and Helicobacter pylori infection: Interactions influence outcome. Cytokine, 29:141–152.
98.
ZengX, LiY, LiuT, ZhangJ. 2012. Diverse H. pylori strains, IL-10 promoter polymorphisms with high morbidity of gastric cancer in Hexi area of Gansu Province, China. Mol Cell Biochem, 361:241–248.
99.
ZhangZ, LiuW, JiaX, GaoY, HemminkiK, LindholmB. 2004. Use of pyrosequencing to detect clinically relevant polymorphisms of genes in basal cell carcinoma. Clin Chim Acta, 342:137–143.
100.
ZoodsmaM, NolteIM, SchipperMet al.2005. Interleukin-10 and Fas polymorphisms and susceptibility for (pre)neoplastic cervical disease. Int J Gynecol Cancer, 15,Suppl 3:282–290.
101.
ZouYF, WangF, FengXLet al.2011. Lack of association of IL-10 gene polymorphisms with prostate cancer: Evidence from 11,581 subjects. Eur J Cancer, 47:1072–1079.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
